Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONTENDER: Phase 1/2A Study of TFH-Targeting COVID-19 Vaccines
NCT06810934Phase 2Recruiting
- Start
- Oct 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, randomised trial of CoTend-s3BXBB and CoTend-BXBB in coronavirus disease 2019 (COVID-19) (16 cohorts). Primary endpoints: Frequency of solicited local reactogenicity adverse events at 7 days, Frequency of solicited systemic reactogenicity adverse events at 7 days and 7 more. Started Oct 2025; status: recruiting.
02
Drugs
CoTend-s3BXBBCoTend-BXBB
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06810934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06810934.